Centre d'Investigation Clinique de Nantes

Subcutaneous isatuximab by on-body-injector plus bortezomib, lenalidomide, and dexamethasone in newly diagnosed transplant-ineligible multiple myeloma: ISASOCUT study

Isatuximab–bortezomib–lenalidomide–dexamethasone (Isa-VRd) has emerged as a standard of care for newly diagnosed multiple myeloma transplant-ineligible patients. A subcutaneous (SC) formulation of isatuximab delivered via an on-body injector (OBI) has been developed to facilitate...

Determinants of failure of midazolam monotherapy during continuous deep sedation until death: evidence from a French cohort in a palliative care unit

Abstract Background Continuous deep sedation until death (CDSUD) is a legally regulated practice in France relying primarily on midazolam as first-line therapy. However, additional sedative agents are frequently required, and determinants of failure of midazolam monotherapy remai...

Design and stability analysis of an underactuated hand with passively rotating fingers

Abstract This paper presents an innovative design and stability analysis of an underactuated robotic finger with spatial mobility, designed to enhance gripping dexterity in robotic hands. The finger architecture incorporates a revolute joint at its base, enabling passive spatial...

Immune‐related adverse events with mogamulizumab in cutaneous T‐cell lymphoma: A multicentre study

BACKGROUND: Mogamulizumab, an anti-CCR4 monoclonal antibody used in advanced mycosis fungoides (MF) and Sezary syndrome (SS), also depletes regulatory T cells, potentially leading to immune-related adverse events (irAEs). Unlike mogamulizumab-associated rash (MAR), other irAEs re...

Serum GFAP and Age Accurately Distinguish AQP4 ‐ IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack

BACKGROUND: Serum neurofilament-light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are associated with multiple sclerosis (MS) activity. This study aimed to identify patient- and disease-level determinants of sNfL and sGFAP and to evaluate their ability to support dif...

A framework for outcome determination of nosocomial pneumonia treatment in ventilated critically ill patients

Abstract Background Treatment failure of hospital-acquired (HAP) and ventilator-associated pneumonia (VAP) is a common endpoint in clinical research, yet the absence of a reproducible definition hampers comparability across studies. We propose an operational framework for assessi...

Acute neuro-inflammatory presentation of ATP1A3 variants: Case reports of three patients with different phenotypes

Background ATP1A3 variants are responsible for rare neurological conditions such as Alternating Hemiplegia of Childhood (AHC), Rapid-onset Dystonia Parkinsonism (RDP), and Cerebellar Ataxia Areflexia Pes Cavus Optic Atrophy and Sensorineural Hearing Loss (CAPOS). Intermediate phe...

Integration of dentists into primary care teams in underserved areas: a qualitative study

Abstract Background Integrating oral health into primary care is increasingly promoted to enhance coordinated, patient-centred care, particularly in underserved areas experiencing workforce shortages. In France, multiprofessional primary care teams organised under the Société Int...

Daratumumab in Combination With High‐Dose Cytarabine and Amsacrine as an Effective Salvage Therapy and Bridge to Allogeneic Hematopoietic Stem Cell Transplantation for Refractory T‐Cell Acute Lymphoblastic Leukemia: A Case Report

ABSTRACT Patients with refractory or relapsed T‐cell acute lymphoblastic leukemia (R/R T‐ALL) have dismal outcomes. While immunotherapies are growing opportunities for B‐cell ALL, targeted therapies for T‐ALL remain limited. The CD38 antigen, steadily expressed on T‐ALL blasts, r...

Protein Binding Determination of Cefepime, Flucloxacillin, Meropenem, Piperacillin and Tazobactam by Ultrafiltration in Critically Ill Patients: The Choice of Device Matters

Therapeutic drug monitoring (TDM) and pharmacokinetic studies of beta-lactam antibiotics in critically ill patients aim to define optimal dosing and require accurate measurement of unbound drug concentrations. This study compared the performance of two ultrafiltration devices, Ce...

Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel

Following the positive findings of the phase 3 CheckMate 238 trial, adjuvant nivolumab has become a standard therapy in patients with completely resected stage III–IV melanoma. The prospective, ongoing AdjuMel study is evaluating the real-world use, effectiveness, and safety of a...

Long‐Term Outcomes of Continent Cutaneous Urinary Diversion in Patients With Neurogenic Lower Urinary Tract Dysfunction: A Monocentric Experience

PURPOSE: To evaluate long-term outcomes and quality of life after continent cutaneous urinary diversion (CCUD) in patients with neurogenic lower urinary tract dysfunction (NLUTD). MATERIALS AND METHODS: We conducted a retrospective, single-center study including all patients with...